Super excited for the new additions to our team and opportunities to innovate together! #letsgo

Actually true 😂 ☔️

Such a privilege to work with Kaye Foster on Agios, Grail, Resilience. More to come. :). archventure.com/arch-venture-p…

Congrats! #rwd

Amazing privilege to work with Rick Klausner (and Yuri Milner) on Rick’s vision to reverse disease, with Hal Barron, Hans Bishop, Ann Lee-Karlon, and so many great scientists who are driven to explore the fascinating biology of cellular rejuvenation.

Paul Thurk started this and really wanted it to happen. Here’s to you, Paul. endpts.com/exclusive-arch…

We’re in the peak of scientific innovation. Even though there are rough waters around us, let’s not stop trying to advance human health 💪🏼

Congrats to $KRTX!! Amazing data. Huge win for patients! statnews.com/2022/08/08/kar… via STAT

Very excited to launch @OrbitalTx with Howard Chang gene yeo Ravi Majeti drew Weissman Giuseppe Ciaramella John Maraganore 🇺🇸🇬🇷🇺🇦🇮🇱 Kristina Burow John Evans Vineeta Agarwala Newpath partners. Thankful for everyone’s support in getting us here and now the real medicine making work begins 💪🏼

Thanks Natasha Loder 🦋🐝 for highlighting the immense opportunity we have for developing better medicines for brain diseases Neumora #deconvolve #precisionneuroscience

Thanks Endpoints News John Carroll for selecting Neumora for Endpoints 11! Honored to be named among other companies pushing the envelope to develop new medicines. - endpts.com/the-endpoints-…

Excited to announce Orbital’s Series A! Thank you to all our supporters and investors in helping us embark on this next wave of RNA medicines. - endpts.com/beams-rna-offs…

Proud to share the news of advancing navacaprant to Ph3s Neumora #mentalhealth #depression Also, welcome Henry Gosebruch! neumoratx.com/news/neumora-t…

Today we celebrate becoming a public company, trading on Nasdaq under the symbol $NMRA. This marks an important step in our journey to confront the global brain disease crisis by redefining neuroscience drug development to make a difference for patients. #IPO

Congratulations Kristina Burow! ⁦⁦Kristina Burow⁩ Truly a privilege and honor to work with and learn from such an incredible person who is shaping the future of medicine #STATUSList @STATnews statnews.com/status-list/20…

HiBio was incubated by ARCH & Monograph in the summer of 2021. It’s been a wild ride, but we’re most excited to see a potentially transformational medicine in the making. Proud & thankful to have been an investor & board member throughout the journey! investors.biogen.com/news-releases/…

ARCH Venture Partners has raised $3 billion for a new fund — one of the largest in the biotech industry, and one the VC firm will use to continue its contrarian investment strategy. statnews.com/2024/09/26/arc…

Great discussion with really interesting ideas. Thanks for listening Dr. Marty Makary Vinay Prasad MD MPH. Hopeful about the potential to accelerate innovation in biopharma.

Today, I’m proud to introduce a revolutionary pathway to drug approvals that will significantly accelerate the delivery of crucial treatments to the American public. I'm committed to fostering innovation that saves lives. The National Priority Voucher program brings the agility

Great progress at Orbital!